Browsing by Author D'Emden, Michael C.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 5 of 5
Issue DateTitleAuthor(s)Citation
2007Abstract 3691: Features Of Metabolic Syndrome Identify Individuals With Type 2 Diabetes Mellitus At High Risk For Cardiovascular Events And Greater Absolute Benefits Of FenofibrateBarter, Philip; Copt, Samuel; Keech, Anthony (Tony); Pardy, Christopher; Best, James; D'Emden, Michael C.; Drury, P; Ehnholm, Christian; FIELD study investigators, Fenofibrate Intervention and Event Lowering in Diabetes; Kesaniemi, Y. Antero; Scott, Russell; Taskinen, M.; Tse, Dana; Central Clinical School: Heart Research Institute; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreAbstract 3691: Features Of Metabolic Syndrome Identify Individuals With Type 2 Diabetes Mellitus At High Risk For Cardiovascular Events And Greater Absolute Benefits Of Fenofibrate, Circulation (Baltimore), vol.116, N/A,pp II_838-N/A
2009Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trialKeech, Anthony (Tony); Li, Li Ping; Rajamani, Kushwin; Voysey, Merryn; Baker, John R.; Best, James; Coleman, Peter G.; D'Emden, Michael C.; FIELD study investigators, Fenofibrate Intervention and Event Lowering in Diabetes; Laakso, Markku; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials CentreEffect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial, The Lancet, vol.373, 9677, 2009,pp 1780-1788
2009The effects of fenofibrate treatment on cardiovascular disease risk in 9795 people with type 2 diabetes and various components of the metabolic syndrome: the FIELD study.Fulcher, Greg; Keech, Anthony (Tony); Pardy, Christopher; Tse, D; D'Emden, Michael C.; Ehnholm, Christian; FIELD study investigators, Fenofibrate Intervention and Event Lowering in Diabetes; O'Brien, Richard; Scott, Russell; Taskinen, M.; Northern Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreThe effects of fenofibrate treatment on cardiovascular disease risk in 9795 people with type 2 diabetes and various components of the metabolic syndrome: the FIELD study., Diabetes Care, vol.32,(3),2009,pp 493-498
2015Guidance concerning the use of glycated haemoglobin (HbA1c) for the diagnosis of diabetes mellitusCheung, Ngai; D'Emden, Michael C.; Jones, Graham R D; Shaw, Jonathan E; Western Clinical School: Medicine (Westmead)Guidance concerning the use of glycated haemoglobin (HbA1c) for the diagnosis of diabetes mellitus, Medical Journal of Australia, vol.203, 2, 2015,pp 89-91
2005Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.Hooper, Michael; D'Emden, Michael C.; Ebeling, Peter R; Ernst, T. F.; Graham, J. J.; Nicholson, Geoff C; Roberts, A. P.; Wenderoth, D; Concord Clinical School: MedicineRisedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial., Climacteric, vol.8,(3),2005,pp 251-262